RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.
You may also be interested in...
Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy
TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
Japan’s 2014 Drug Price Reforms Extend Price Premium Program
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.